IN THIS ISSUE OF CIRCULATION, Yusuf et al. ' have written a provocative review of some methodologic problems associated with nonrandomized, naturalistic studies of the efficacy and safety of drugs. Because of these problems, they contend that retrospective analysis of data bases collected for other purposes is not a useful approach for evaluating the effects of a treatment like digitalis. We strenuously disagree with this point of view because it creates a catch-22: How are we to generate hypotheses for large-scale clinical trials without such retrospective analyses?
Some of the material in the review by Yusuf et al. is valuable, especially their warning concerning the phenomenon of undercorrection. When a confounding variable is measured with random error, its control will result in the removal of only a fraction of its effect on the association between the risk factor under study and the outcome variable.2 Some of the material is misleading, however, and worse, they make no recommendation at all about how to proceed to resolve the digitalis controversy.
The assertion that "other investigators . . . have found no evidence that digitalis is harmful" is inaccurate. On the contrary, the findings in four recent publications were that digitalis was harmful.3-In each of these studies, the effect of digitalis was of borderline statistical significance after confounding variables were controlled for. Such concordance among independent nonrandomized studies lends credence to the validity of the conclusion that digitalis may be harmful to patients after myocardial infarction.
The word "impossible" is too strong in the state-ment, "moderate biases in data-base analyses make it impossible to reliably assess [treatment] effects." Difficult, yes. Impossible, perhaps also yes if one is referring to only a single study. But not impossible if one is referring to a series of independent studies by investigators on different sides of the digitalis controversy.
To assert impossibility under all circumstances is to condemn as fundamentally invalid all nonexperimental disciplines, including epidemiology. The description of how we combined evidence from our and earlier studies is misleading. Insufficient data were reported in earlier studies to permit a pooling of the results in the classic sense. Only the significance levels, not the data, were therefore pooled.5
It was reassuring to read that data bases collected for other purposes "may even be used to generate hypotheses concerning treatment comparisons." Was this not, in fact, what was done by Moss et al.7 and by us5 in our recent article? Does one not generate a hypothesis by providing evidence based on data analysis that the hypothesis may be true? Perhaps Yusuf et al. are insisting that hypotheses be generated by speculation, not numerical evidence.
Yusuf et al. make no recommendation about the next step in resolving the digitalis controversy, and it is not clear just what they are suggesting. Is it that digitalis has not yet been proven to be harmful when used by patients who have recently experienced a myocardial infarction? If so, they are correct, but hardly the first to point this out. 5 7 Is it that only a randomized trial will settle the matter? Again they're correct, but again others had proposed this earlier.5' Is it that the Clinical Trials and Biometrics Research Branches of the NHLBI are urging the initiation of such a trial? If so, they deserve approbation and are to be thanked for accepting as suggestive the evidence from the nonrandomized studies they reviewed. Or is it, finally, that there is not yet any basis for such a trial? If so, one has the right to demand of them just what kind of evidence they would accept as suggestive enough to justify a randomized trial. We contend that the sum of the evidence from a series of retrospective analyses, while not Vol. 73, No. 1, January 1986 19 capable of producing a definitive conclusion, is an acceptable way of generating a hypothesis that then becomes a candidate for the precious resources available for full-scale randomized trials.
